Chimeric nanoparticles for targeting mitochondria in cancer cells

Show simple item record

dc.contributor.author Bajpai, Aman
dc.contributor.author Desai, Nakshi
dc.contributor.author Pandey, Shalini
dc.contributor.author Shukla, Chinmayee
dc.contributor.author Datta, Bhaskar
dc.contributor.author Basu, Sudipta
dc.coverage.spatial United Kingdom
dc.date.accessioned 2022-02-03T08:03:06Z
dc.date.available 2022-02-03T08:03:06Z
dc.date.issued 2022-01
dc.identifier.citation Bajpai, Aman; Desai, Nakshi; Pandey, Shalini; Shukla, Chinmayee; Datta, Bhaskar and Basu, Sudipta, “Chimeric nanoparticles for targeting mitochondria in cancer cells”, Nanoscale Advances, DOI: 10.1039/D1NA00644D, vol. 4, no. 4, pp. 1112-1118, Jan. 2022. en_US
dc.identifier.issn 2516-0230
dc.identifier.uri https://doi.org/10.1039/D1NA00644D
dc.identifier.uri https://repository.iitgn.ac.in/handle/123456789/7444
dc.description.abstract Mitochondrial dysfunction is implicated in myriad diseases, including cancer. Subsequently, targeting mitochondrial DNA (mt-DNA) in cancer cells has emerged as an unorthodox strategy for anti-cancer therapy. However, approaches targeting only one component of the mitochondrial "central dogma" can be evaded by cancer cells through various mechanisms. To address this, herein, we have engineered mitochondria-targeting cholesterol-based chimeric nanoparticles (mt-CNPs) consisting of cisplatin, camptothecin, and tigecycline, which can simultaneously impair mt-DNA, mitochondrial topoisomerase I (mt-Top1), and mitochondrial ribosomes. mt-CNPs were characterized as being positively charged, spherical in shape, and 187 nm in diameter. Confocal microscopy confirmed that mt-CNPs efficiently localized into the mitochondria of A549 lung cancer cells within 6 h, followed by mitochondrial morphology damage and the subsequent generation of reactive oxygen species (ROS). mt-CNPs showed remarkable cancer-cell killing abilities compared to free-drug combinations in A549 (lung), HeLa (cervical), and MCF7 (breast) cancer cells. These mitochondria-targeting lipidic chimeric nanoparticles could be explored further to impair multiple targets in mitochondria, helping researchers to gain an understanding of mitochondrial translational and transcriptional machinery and to develop new strategies for cancer therapy.
dc.description.statementofresponsibility by Aman Bajpai, Nakshi Desai, Shalini Pandey, Chinmayee Shukla, Bhaskar Datta and Sudipta Basu
dc.format.extent vol. 4, no. 4, pp. 1112-1118
dc.language.iso en_US en_US
dc.publisher Royal Society of Chemistry en_US
dc.subject Chimeric nanoparticles en_US
dc.subject Mitochondrial dysfunction en_US
dc.subject Mitochondria-targeting cholesterol-based chimeric nanoparticles (mt-CNPs) en_US
dc.subject mitochondrial topoisomerase I (mt-Top1) en_US
dc.subject cancer therapy en_US
dc.title Chimeric nanoparticles for targeting mitochondria in cancer cells en_US
dc.type Article en_US
dc.relation.journal Nanoscale Advances


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search Digital Repository


Browse

My Account